文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

低水平HIV病毒血症期间广泛耐药支持降低资源有限地区换药阈值

Extensive drug resistance during low-level HIV viraemia while taking NNRTI-based ART supports lowering the viral load threshold for regimen switch in resource-limited settings: a pre-planned analysis from the SESOTHO trial.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

SESOTHO试验预设嵌套分析评估接受NNRTI一线ART且低水平病毒血症(100-999拷贝/mL)患者的耐药突变。基线84%(31/37)携带有对当前方案至少两种药物高水平耐药;36周时对照组81%(17/21)仍耐药,换药组5例持续病毒血症者未检出PI耐药。结果支持未来WHO指南降低触发二线ART的病毒载量阈值。

要点

  • 低水平病毒血症(100-999拷贝/mL)者多数已存在需调整ART的耐药突变
  • 换用PI为基础二线方案者36周时未检出PI相关耐药
  • 支持未来WHO指南降低换药病毒载量阈值

核心结论

  • 在NNRTI一线ART低水平病毒血症者中,多数携带需调整ART的耐药突变,支持降低换药病毒载量阈值。

研究设计与样本

  • SESOTHO试验预设嵌套分析,2017-2020年在莱索托纳入80例NNRTI一线ART且HIV-1病毒载量100-999拷贝/mL者,1:1随机换PI二线方案或继续一线。

主要发现

  • 基线37/80(46%)获测序,其中31/37(84%)对当前方案至少两种药物高水平耐药。
  • 36周时21例对照中17/21(81%)对当前方案至少两种药物耐药。
  • 36周时5例换药组持续病毒血症者未检出PI相关耐药。

关键数值与推荐

  • WHO指南将治疗失败病毒载量阈值定为1000拷贝/mL。
  • 基线84%(31/37)对当前方案至少两种药物高水平耐药。
  • 36周对照组81%(17/21)对当前方案至少两种药物耐药。

临床怎么用

  • 对NNRTI一线ART且病毒载量100-999拷贝/mL者应警惕耐药并考虑调整方案。
  • 换用PI为基础二线方案在持续低水平病毒血症者中未检出PI耐药。

局限性

  • 基线仅37/80(46%)获测序数据。
  • 36周仅26/48(54%)无病毒抑制者获测序数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: WHO guidelines on ART define the HIV-1 viral load (VL) threshold for treatment failure at 1000 copies/mL. The Switch Either near Suppression Or THOusand (SESOTHO) trial, conducted in Lesotho from 2017 to 2020, found that patients with persistent viraemia below this threshold (100-999 copies/mL) benefit from switching to second-line ART. This pre-planned nested study assesses the prevalence of resistance-associated mutations (RAMs) in SESOTHO trial participants. METHODS: The SESOTHO trial [registered at ClinicalTrials.gov (NCT03088241)] enrolled 80 persons taking NNRTI-based first-line ART with low-level HIV-1 viraemia (100-999 copies/mL) and randomized them (1:1) to switch to a PI-based second-line regimen (switch) or continue on first-line therapy (control). We sequenced relevant regions of the viral pol gene using plasma samples obtained at enrolment and 36 weeks. RAMs were classified with the Stanford HIV Drug Resistance Database. RESULTS: Sequencing data were obtained for 37/80 (46%) participants at baseline and 26/48 (54%) participants without viral suppression to <50 copies/mL at 36 weeks (21 control participants and 5 switch participants). At baseline, 31/37 (84%) participants harboured high-level resistance to at least two drugs of their current regimen. At 36 weeks, 17/21 (81%) control participants harboured resistance to at least two drugs of their current regimen, while no PI-associated resistance was detected in the 5 switch participants with ongoing viraemia. CONCLUSIONS: Among persons with low-level viraemia while taking NNRTI-based first-line ART enrolled in the SESOTHO trial, the majority harboured HIV-1 with RAMs that necessitate ART modification. These findings support lowering the VL threshold triggering a switch to second-line ART in future WHO guidelines.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Brown JA, Amstutz A, Nsakala BL, et al. Extensive drug resistance during low-level HIV viraemia while taking NNRTI-based ART supports lowering the viral load threshold for regimen switch in resource-limited settings: a pre-planned analysis from the SESOTHO trial. J Antimicrob Chemother. 2021. PMID: 33599270. doi:10.1093/jac/dkab025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。